Compare Expedia Group Inc (EXPE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Expedia Group Inc trades at $264.32 (market cap $32.06B), while Regeneron Pharmaceuticals Inc trades at $676.01 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.2× Expedia Group Inc's market cap, and Expedia Group Inc pays the higher dividend (0.66%). Which is the better fit depends on your goals.
| EXPE | REGN | |
|---|---|---|
Market Cap | $32.06B | $69.66B |
Sector | Consumer Cyclical | Health |
52-Week High | $301.31 | $812.27 |
52-Week Low | $178.06 | $542.52 |
Enterprise Value | $30.97B | $63.61B |
Dividend Yield | 0.66% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $266.28, showing modest daily gains of 0.24%. The stock exhibits a bullish technical signal, supported by strong earnings beats in recent quarters and robust revenue growth from $11.7B in 2022 to $14.7B in 2025. The company maintains high profitability with a 90.27% gross margin and recently announced a strategic partnership with Allegiant Travel Company, expanding its online travel agency network.
The investment outlook is positive with analyst consensus at $292.09, representing 9.7% upside potential. Key opportunities include continued travel sector growth and operational efficiency gains from recent technology investments. Primary risks involve macroeconomic sensitivity affecting travel demand and competitive pressures in the online travel market. The company's strong cash flow generation supports shareholder returns through dividends and potential buybacks.
Regeneron (REGN) trades at $656.11, down 1.05% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and has beaten EPS estimates for three consecutive quarters. Recent positive news includes FDA and EMA acceptance of cemdisiran for gMG treatment and selection for an FDA manufacturing review pilot program, reinforcing growth prospects.
Outlook remains positive with a consensus price target of $764.50, implying 16.5% upside. Key opportunities include earnings momentum and regulatory advancements, while risks involve competitive pressures and dependence on key drug performance. Institutional sentiment is strongly bullish with 69% buy ratings, though legal investigations and market volatility warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
